ClinicalTrials.gg
RecruitingNCT07566390Updated Sep 9, 2026

A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

A Phase 1 interventional study of NNC0113-5840 and Placebo in Obesity and Overweight, sponsored by Novo Nordisk A/S. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 210 studies in Obesity by Novo Nordisk A/S — 51 open to participants now, 69 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Planned enrollment
138th of 169
48 · median 134
Started
2026
with 49 others
Phase 1
87 of 210
24 open now
Primary completion
2027-01
later than 8 of 68 live
Registered
178th of 210
by date

Among the 210 studies in Obesity by Novo Nordisk A/S, this one is the 138th largest by planned enrollment of the 169 interventional ones that give a count, is one of 50 that started in 2026, is one of 87 in phase 1, reaches primary completion later than 8 of the 68 other live ones, and was the 178th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

51 of the 210 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

46 more — sign in →

By country, each count listing its studies:

All 51 open studies →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female
  2. Age 18-55 years (both inclusive) at the time of signing the .
  3. (BMI) between 25.0 and 34.9 kilogram per meter square (kg/m2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
  4. Considered eligible based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit and visit 2, day -1, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected to study intervention(s) or related products.
  2. Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  3. Glycosylated () more than or equal to (≥) 6.5 percent (%) [48 millimole per mole (mmol/mol)] at screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Cohort 1 NNC0113-5840

    Participants will be randomized to receive NNC0113-5840 single dose level 1 subcutaneously.

    Drug: NNC0113-5840

  • Experimental
    Cohort 2 NNC0113-5840

    Participants will be randomized to receive NNC0113-5840 single dose level 2 subcutaneously.

    Drug: NNC0113-5840

  • Experimental
    Cohort 3 NNC0113-5840

    Participants will be randomized to receive NNC0113-5840 single dose level 3 subcutaneously.

    Drug: NNC0113-5840

  • Experimental
    Cohort 4 NNC0113-5840

    Participants will be randomized to receive NNC0113-5840 single dose level 4 subcutaneously.

    Drug: NNC0113-5840

  • Experimental
    Cohort 5 NNC0113-5840

    Participants will be randomized to receive NNC0113-5840 single dose level 5 subcutaneously.

    Drug: NNC0113-5840

  • Experimental
    Cohort 6 NNC0113-5840

    Participants will be randomized to receive NNC0113-5840 single dose level 6 subcutaneously.

    Drug: NNC0113-5840

  • Placebo comparator
    Placebo matching NNC0113-5840

    Participants will receive placebo matched to NNC0113-5840 subcutaneously.

    Drug: Placebo

Interventions

  • DrugNNC0113-5840

    NNC0113-5840 will be administered subcutaneously using needle and syringe in a lifted fold of the abdominal skin.

  • DrugPlacebo

    Placebo matched to NNC0113-5840 will be administered subcutaneously using needle and syringe in a lifted fold of the abdominal skin.

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAEs)

    Measured as number of events.

    Time frame: From time of dosing (day 1) up to day 43

Secondary outcomes

  1. AUC: Area under the NNC0113-5840 plasma concentration time-curve

    Measured as hours\*nanomole per liter (h\*nmol/L)

    Time frame: From pre-dose (day 1) up to day 43

  2. Cmax: Maximum observed NNC0113-5840 plasma concentration

    Measured as nanomoles per liter (nmol/L)

    Time frame: From pre-dose (day 1) up to day 43

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2027, 8 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 8 months is below that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 5, 2026
StartActual
May 1, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07566390
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 5, 2026
Start date
May 1, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion